I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

James Epperson

Type or print name

May 22, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

EXAMINER: Rebecca L. Anderson

Amy Q. Han, et al

ART UNIT: 1626

APPLICATION NO: 10/015,328 FILED: December 12, 2001

FOR: Imidazolidinones and Their Related Derivatives as Hepatitis C Virus RECEIVED

MAY 2 7 2003

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references were cited in a search report in a corresponding PCT International application. Copies of these references and the search report are enclosed herewith.

Also, copies of the other cited references are enclosed herewith.

05/27/2003 SLUANG1

00000040 193880

10015328

01 FC:1806

180.00 CH



CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

James Epperson Type or print name

May 22, 2003 Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

EXAMINER: Rebecca L. Anderson

Amy Q. Han, et al

ART UNIT: 1626

APPLICATION NO: 10/015,328

FILED: December 12, 2001

FOR: Imidazolidinones and Their Related Derivatives as Hepatitis C Virus

NS3 Protease Inhibitors

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 203-677-6974

Date:

James Epperson Agery for Applicant Reg. No. 52,867

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 203-677-6974

Date:

James Epperson Agent for Applicants Reg. No. 52,867

Sheet 1 of 1

FORM PTO-1449 (REV. 7-85)

EXAMINER

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary) MAY 2 7 2003

ATTY. DOCKET NO. PH-7203 NP APPLICATION NO. 10/015,328 APPLICANT Amy Q. Han, et al FILING DATE December 12, 2001

Group 1626

ILS PATENT DOCUMENTS

EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLA	SS SUBCLA	ss F	ILING DATE
INITIAL	AA	DOCUMENT NUMBER	DATE	NAME				
	AB				-			
	AC							
	AD							
	AE							
	AF							
	AG							
	АН							
	AI							
	AJ							
	AK							
	AL							
			FOREIG	N PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	ISLATION NO
	АМ	WO 98/17679	4/30/98	PCT Patent Application				
	AN	14/0 00/00400	1/31/02	PCT Patent Application				
		WO 02/08198	., 0 ., 0=	•		1	1	
	AO	WO 02/08198 / EP 0932617	4/30/98	European Patent Application				
				European Patent Application PCT Patent Application				
	AO	EP 0932617	4/30/98				+=-	
	AO AP	EP 0932617 WO 99/50230 EP 0471651	4/30/98 10/7/99 2/19/92	PCT Patent Application	nt pages, E	itc.)		
	AO AP AQ	EP 0932617 WO 99/50230 EP 0471651	4/30/98 10/7/99 2/19/92	PCT Patent Application European Patent Application	nt pages, E	itc.)		
	AO AP	EP 0932617 WO 99/50230 EP 0471651	4/30/98 10/7/99 2/19/92	PCT Patent Application European Patent Application	nt pages, E	itc.)		
	AO AP AQ	EP 0932617 WO 99/50230 EP 0471651	4/30/98 10/7/99 2/19/92	PCT Patent Application European Patent Application	nt pages, E	ite.)		
	AO AP AQ	EP 0932617 WO 99/50230 EP 0471651	4/30/98 10/7/99 2/19/92	PCT Patent Application European Patent Application	nt pages, E	itc.)		

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

DATE CONSIDERED